SOLLIS THERAPEUTICS, INC.
Sollis Therapeutics, headquartered in Columbus, OH, was formed and seeded by NIT in early 2017, to develop novel non-steroid, non-opioid analgesics. Sollis’ first product, is an extended release combination analgesic and anti-inflammatory medication purpose-built for targeted local delivery for the treatment of sciatica and other neuropathic pain syndromes. www.SollisTX.com
VERESSA MEDICAL, INC.
Veressa, an early-stage seed company focused on developing a next-generation neuromodulation system, was formed and seeded by NIT in late 2016 around a solution conceived by NIT. The company is currently developing and testing its technology in trials for its first targeted indication, and intends to raise its first institutional round of capital in the second half of 2018.